Sophiris Bio has reported a net loss of $5.62m, or $0.03 per share, for the third quarter ended 30 September 2012 compared to a net loss of $2.97m, or $0.02 per share, for the third quarter ended 30 September 2011. Expenses for third ...
Tags: Sophiris Bio, net loss, Q3 Net Loss, PRX302 clinical program